[go: up one dir, main page]

ES2141137T3 - Agentes terapeuticos para la enfermedad de parkinson. - Google Patents

Agentes terapeuticos para la enfermedad de parkinson.

Info

Publication number
ES2141137T3
ES2141137T3 ES93307654T ES93307654T ES2141137T3 ES 2141137 T3 ES2141137 T3 ES 2141137T3 ES 93307654 T ES93307654 T ES 93307654T ES 93307654 T ES93307654 T ES 93307654T ES 2141137 T3 ES2141137 T3 ES 2141137T3
Authority
ES
Spain
Prior art keywords
straight
alkoxy
branched chain
naphthyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93307654T
Other languages
English (en)
Inventor
Fumio Suzuki
Junichi Shimada
Nobuaki Koike
Joji Nakamura
Shizuo Shiozaki
Shunji Ichikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of ES2141137T3 publication Critical patent/ES2141137T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PRESENTAN DERIVADOS DE LA XANTINA COMO AGENTES TERAPEUTICOS PARA LA ENFERMEDAD DE PARKINSON, QUE TIENEN LA FORMULA: EN QUE: R1 Y R2 REPRESENTAN CADA UNO METILO O ETILO; R3 REPRESENTA HIDROGENO, ALKILO C1-C6 DE CADENA RECTA O RAMIFICADA O ALKINILO O ALKELINO C2-C6 DE CADENA RECTA O RAMIFICADA; R4 REPRESENTA CICLOALKILO C3-C8; UN GRUPO -(CH2)N-R5 DONDE N ES 0 O UN ENTERO DE 1 A 4 Y R5 REPRESENTA FENILO, NAFTILO O UN GRUPO HETEROCICLICO O UN GRUPO FENILO, NAFTILO O HETEROCICLICO SUSTITUIDO QUE CONTIENE DE 1 A 4 SUSTITUYENTES SELECCIONADOS DEL ALKILO C1-C6, ALCOXI C1-C6, HIDROXI, HALOGENO, NITRO, AMINO, MONO O DIALKILAMINO C1-C6, TIFLUOROMETILO, BENCILOXI, FENILO, FENOXI O ALCOXI C1-C6 SUSTITUIDO POR HIDROXI, ALCOXI C1-C6, HALOGENO, NITRO, AZIDA, CARBOXI O (C1-C6 ALCOXI)CARBONILO; O UN GRUPO DONDE Y1 E Y2 REPRESENTAN CADA UNO HIDROGENO, HALOGENO O ALKILO C1-C6 DE CADENA RECTA O RAMIFICADA; Y Z REPRESENTA UN GRUPO EN QUE R6 REPRESENTA HIDROGENO, HIDROXI, ALKILO C1-C6 DE CADENA RECTA O RAMIFICADA, ALCOXI C1-C6 DE CADENA RECTA O RAMIFICADA, HALOGENO, NITRO O AMINO Y M REPRESENTA UN ENTERO DE 1 A 4; UN GRUPO FENILO, NAFTILO O HETEROCICLICO O UN GRUPO FENILO, NAFTILO O HETEROCICLICO SUSTITUIDO IGUAL A COMO SE HA DEFINIDO EN R5; Y X1 Y X2 REPRESENTA CADA UNO O O S; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS.
ES93307654T 1992-09-28 1993-09-28 Agentes terapeuticos para la enfermedad de parkinson. Expired - Lifetime ES2141137T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP25783492 1992-09-28

Publications (1)

Publication Number Publication Date
ES2141137T3 true ES2141137T3 (es) 2000-03-16

Family

ID=17311787

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93307654T Expired - Lifetime ES2141137T3 (es) 1992-09-28 1993-09-28 Agentes terapeuticos para la enfermedad de parkinson.

Country Status (10)

Country Link
EP (1) EP0590919B1 (es)
JP (1) JP2613355B2 (es)
AT (1) ATE188216T1 (es)
CA (1) CA2107014C (es)
DE (1) DE69327438T2 (es)
DK (1) DK0590919T3 (es)
ES (1) ES2141137T3 (es)
GR (1) GR3032972T3 (es)
NO (1) NO304946B1 (es)
PT (1) PT590919E (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
ATE218139T1 (de) * 1994-02-23 2002-06-15 Kyowa Hakko Kogyo Kk Xanthin-derivate
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
JP2001523213A (ja) 1994-12-13 2001-11-20 ユーロ−セルティーク，エス．エイ． 三置換チオキサンチン類
ATE247116T1 (de) 1994-12-13 2003-08-15 Euro Celtique Sa Arylthioxanthine
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
EP1016407B1 (en) * 1997-09-05 2006-05-10 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for treating brain ischemia
AU1507099A (en) * 1997-12-15 1999-07-05 Kyowa Hakko Kogyo Co. Ltd. Preventives/remedies for sleep disturbance
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
AU4431000A (en) * 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
ATE319452T1 (de) * 1999-10-29 2006-03-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen essstörungen
MXPA03007349A (es) * 2001-02-24 2003-12-04 Boehringer Ingelheim Pharma Derivados de xantina, su preparacion y su empleo como medicamentos.
TWI330183B (es) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
CA2525037C (en) * 2003-05-09 2011-12-20 Kyowa Hakko Kogyo Co., Ltd. Microcrystals of (e)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine
TW200507882A (en) * 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
TWI346114B (en) * 2003-09-29 2011-08-01 Method for stabilization of diarylvinylene compounds
ES2532479T3 (es) * 2004-01-28 2015-03-27 Kyowa Hakko Kirin Co., Ltd. Agentes para el tratamiento de la migraña
WO2006059713A1 (ja) * 2004-12-03 2006-06-08 Kyowa Hakko Kogyo Co., Ltd. 薬物依存症の予防および／または治療剤
MX2009006346A (es) * 2006-12-22 2010-03-03 Sanol Arznei Schwarz Gmbh Derivados de 8-etinilxantina como antagonistas de receptores de a2a selectivos.
US8871751B2 (en) 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
US8791126B2 (en) 2010-11-24 2014-07-29 Yamasa Corporation 2-alkynyl-N9-propargyladenine and medicinal use thereof
RU2477726C1 (ru) * 2011-10-18 2013-03-20 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные феноксиуксусные кислоты, их эфиры и амиды, включающие 2,6-диоксо-2,3,6,7-тетрагидро-1н-пурин-8-иловый фрагмент, - антагонисты аденозинового a2a рецептора и их применение
RU2480469C1 (ru) * 2012-02-03 2013-04-27 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Замещенные 1,3-диэтил-8-винил-7-метил-3,7-дигидро-пурин-2,6-дионы-антагонисты аденозинового a2a рецептора и их применение
CN104744464B (zh) * 2013-11-15 2016-09-21 南京华威医药科技开发有限公司 伊曲茶碱晶型
CN105884776A (zh) * 2014-11-05 2016-08-24 南京瑞天医药科技有限公司 一种伊曲茶碱的新晶型及其制备方法
WO2016148260A1 (ja) * 2015-03-17 2016-09-22 協和発酵キリン株式会社 医薬組成物
WO2016148261A1 (ja) * 2015-03-19 2016-09-22 協和発酵キリン株式会社 レビー小体病の治療および／または予防剤
WO2020125779A1 (en) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CN111333648B (zh) * 2019-04-24 2021-05-11 东莞市东阳光新药研发有限公司 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
CN110041331B (zh) * 2019-05-17 2020-08-07 广东东阳光药业有限公司 苯乙烯基黄嘌呤衍生物及其用途
CN112300165B (zh) * 2019-11-11 2022-03-04 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111018856B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111072663B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
KR20220152308A (ko) * 2020-03-10 2022-11-15 마블 바이오테크놀러지 장애 치료를 위한 퓨린 화합물
CN111548351B (zh) * 2020-06-22 2021-03-12 连云港贵科药业有限公司 一种伊曲茶碱的合成方法
CN113248505B (zh) * 2021-06-09 2021-09-21 南京安杰新生物医药有限公司 伊曲茶碱去甲基杂质的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2729642A (en) * 1954-08-13 1956-01-03 Chattanooga Medicine Co Water soluble salts of 8-(para-aminobenzyl) caffeine and method for their preparation
GB1280424A (en) * 1969-07-30 1972-07-05 Parke Davis & Co Novel xanthine compounds and means for obtaining the same
US3624216A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-inflammatory agents
US3624215A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-anxiety agents
US3900474A (en) * 1973-05-14 1975-08-19 Kendall & Co Trifluoroalkyl, fluorobenzyl, pentafluorobenzyl, fluorobenzenesulfonyl, and pentafluorobenzenesulfonyl theophyllines
ES8303412A1 (es) * 1981-10-06 1983-02-01 Invest Tecnica Aplicada Procedimiento de obtencion de nuevas xantinas con actividad farmacologica
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
FR2531085A1 (fr) * 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
HU197746B (en) * 1985-09-05 1989-05-29 Sandoz Ag Process for producing xantin derivatives and pharmaceutical compositions containing them
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
CA2094270C (en) * 1990-10-18 1997-01-21 Fumio Suzuki Xanthine derivatives
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease

Also Published As

Publication number Publication date
PT590919E (pt) 2000-04-28
CA2107014A1 (en) 1994-03-29
EP0590919B1 (en) 1999-12-29
DE69327438D1 (de) 2000-02-03
JP2613355B2 (ja) 1997-05-28
DK0590919T3 (da) 2000-04-17
JPH06211856A (ja) 1994-08-02
NO933452L (no) 1994-03-29
EP0590919A1 (en) 1994-04-06
GR3032972T3 (en) 2000-07-31
DE69327438T2 (de) 2000-06-21
NO304946B1 (no) 1999-03-08
CA2107014C (en) 2000-06-13
NO933452D0 (no) 1993-09-27
ATE188216T1 (de) 2000-01-15

Similar Documents

Publication Publication Date Title
ES2141137T3 (es) Agentes terapeuticos para la enfermedad de parkinson.
EP0628311A4 (en) ANTIDEPRESSOR.
MX9204746A (es) Nuevos derivados de tiazolilbenzofuranos, procedimientos para la preparacion de los mismos y las composiciones farmaceuticas que los contienen.
DE69021472D1 (de) Pyrazolderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellung.
NO903438L (no) Fremgangsmaate for fremstilling av tiazolderivater.
ES2018832B3 (es) Derivados de amida.
BR1100636A (pt) Agente terapêutico para o mal de parkinson, e, derivado da xantina
EP1034783A4 (en) AMIDE DERIVATIVES
PT87954A (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de dioxopiperidina, com efeito antipsicotico
HU9202849D0 (en) Method for producing n,n',n-trisubstituted- 5-bis-amino-methylene-1,3-dioxane-4,6-dione derivatives and pharmaceutical preparatives containing them

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 590919

Country of ref document: ES